PPARG and melanoma: The PPARγ agonists rosiglitazone, troglitazone,pioglitazone, and ciglitazone showed an increase in cell proliferation of allsix melanoma cell lines tested in low concentrations (3 μM), however, in higherconcentrations (>30 μM) a significant growth-inhibitory effect wasobserverd [28].